|
|
 |
|
Viewing report
|
|
|
|
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
Fuji-Keizai USA, Inc, Aug 2004, Pages: 202
This report is about the market for molecular biomarkers for clinical diagnostics and for drug discovery and development. The research reviews the market segments by major diseases, by application areas, and by technologies.
This study surveyed the activities of more than 60 companies that are participating in this industry. The report analyzed the future direction of biomarkers, molecular diagnostics and pharmaco-genomic tests used in drug discovery and development.
This new report has found that the worldwide market size for molecular biomarkers, diagnostics and related molecular clinical lab services in 2003 was about $6.1 billion. The diagnostics and pharmaceutical industries each face numerous challenges that could be helped with newer business approaches that are discussed in this report. The molecular diagnostics companies are set for strong growth.
The report discusses new FDA initiatives to accelerate the approvals of diagnostics and new drugs by integrating biomarkers and pharmacogenomic tests into the drug discovery and development steps including clinical trials. The report discusses these important items with interesting and useful findings.
This study uses more than 23 figures and 47 tables to illustrate the findings. Detailed information includes several large tables about company activities, strategic alliances, technologies and so on. Twenty-three companies are profiled including details about contact information, business overview, financial details and product pipelines.
This report is available in either English or Japanese
|
|
|
|
